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Antimalarial chemoprophylaxis for forest goers in
southeast Asia: an open-label, individually randomised
controlled trial
Rupam Tripura, Lorenz von Seidlein, Siv Sovannaroth, Thomas J Peto, James J Callery, Meas Sokha, Mom Ean, Chhouen Heng,
Franca Conradis-Jansen, Wanassanan Madmanee, Pimnara Peerawaranun, Naomi Waithira, Panarasri Khonputsa, Monnaphat Jongdeepaisal,
Kulchada Pongsoipetch, Paphapisa Chotthanawathit, Ung Soviet, Christopher Pell, Jureeporn Duanguppama, Huy Rekol, Joel Tarning,
Mallika Imwong, Mavuto Mukaka, Nicholas J White, Arjen M Dondorp, Richard J Maude

Summary

Background Malaria in the eastern Greater Mekong subregion has declined to historic lows. Countries in the Greater
Mekong subregion are accelerating malaria elimination in the context of increasing antimalarial drug resistance.
Infections are now increasingly concentrated in remote, forested foci. No intervention has yet shown satisfactory
efficacy against forest-acquired malaria. The aim of this study was to assess the efficacy of malaria chemoprophylaxis
among forest goers in Cambodia.
Methods We conducted an open-label, individually randomised controlled trial in Cambodia, which recruited
participants aged 16–65 years staying overnight in forests. Participants were randomly allocated 1:1 to antimalarial
chemoprophylaxis, a 3-day course of twice-daily artemether–lumefantrine followed by the same daily dosing once
a week while travelling in the forest and for a further 4 weeks after leaving the forest (four tablets per dose; 20 mg
of artemether and 120 mg of lumefantrine per tablet), or a multivitamin with no antimalarial activity. Allocations
were done according to a computer-generated randomisation schedule, and randomisation was in permuted blocks
of size ten and stratified by village. Investigators and participants were not masked to drug allocation, but laboratory
investigations were done without knowledge of allocation. The primary outcome was a composite endpoint of
either clinical malaria with any Plasmodium species within 1–28, 29–56, or 57–84 days, or subclinical infection
detected by PCR on days 28, 56, or 84 using complete-case analysis of the intention-to-treat population. Adherence
to study drug was assessed primarily by self-reporting during follow-up visits. Adverse events were assessed in the
intention-to-treat population as a secondary endpoint from self-reporting at any time, plus a physical examination
and symptom questionnaire at follow-up. This trial is registered at ClinicalTrials.gov (NCT04041973) and is
complete.
Findings Between March 11 and Nov 20, 2020, 1480 individuals were enrolled, of whom 738 were randomly assigned
to artemether–lumefantrine and 742 to the multivitamin. 713 participants in the artemether–lumefantrine group and
714 in the multivitamin group had a PCR result or confirmed clinical malaria by rapid diagnostic test during followup. During follow-up, 19 (3%, 95% CI 2–4) of 713 participants had parasitaemia or clinical malaria in the artemether–
lumefantrine group and 123 (17%, 15–20) of 714 in the multivitamin group (absolute risk difference 15%, 95% CI
12–18; p<0·0001). During follow-up, there were 166 malaria episodes caused by Plasmodium vivax, 14 by Plasmodium
falciparum, and five with other or mixed species infections. The numbers of participants with P vivax were 18 (3%,
95% CI 2–4) in the artemether–lumefantrine group versus 112 (16%, 13–19) in the multivitamin group (absolute risk
difference 13%, 95% CI 10–16; p<0·0001). The numbers of participants with P falciparum were two (0·3%, 95% CI
0·03–1·01) in the artemether–lumefantrine group versus 12 (1·7%, 0·9–2·9) in the multivitamin group (absolute risk
difference 1·4%, 95% CI 0·4–2·4; p=0·013). Overall reported adherence to the full course of medication was 97%
(95% CI 96–98; 1797 completed courses out of 1854 courses started) in the artemether–lumefantrine group and 98%
(97–98; 1842 completed courses in 1885 courses started) in the multivitamin group. Overall prevalence of adverse
events was 1·9% (355 events in 18 806 doses) in the artemether–lumefantrine group and 1·1% (207 events in
19 132 doses) in the multivitamin group (p<0·0001).
Interpretation Antimalarial chemoprophylaxis with artemether–lumefantrine was acceptable and well tolerated and
substantially reduced the risk of malaria. Malaria chemoprophylaxis among high-risk groups such as forest workers
could be a valuable tool for accelerating elimination in the Greater Mekong subregion.
Funding The Global Fund to Fight AIDS, Tuberculosis and Malaria; Wellcome Trust.
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY
4.0 license.
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Research in context
Evidence before this study
We searched PubMed for articles in English published from
database inception until June 30, 2022, using the terms
antimalarial AND prophylaxis AND malaria, filtering the
search for Clinical Trials, Meta-Analyses, Randomized
Controlled Trial, and Humans, and screening for clinical trials
and systematic reviews. The search resulted in 104 articles.
Of these, 19 described systematic reviews and meta-analyses.
Of the remaining 85 describing clinical trials, five were
controlled human challenge models; 52 presented
intermittent preventive treatment in infants, children,
or pregnant women; four assessed seasonal malaria
chemoprophylaxis; and 17 investigated the malariaprophylactic effects of co-trimoxazole or antiretrovirals in
people with HIV (n=13), travellers (n=2), or people with sickle
cell anaemia (n=2). Of the remaining seven studies, one in
Kenyan school children found proguanil to be effective in
preventing falciparum malaria. Five trials assessed
chemoprophylaxis efficacy in Asian adults, including
two placebo-controlled trials of monthly, single-dose
naphthoquine–azithromycin in a low-risk setting on the
China–Myanmar border that showed more than 90% efficacy
in preventing malaria, with a good safety profile and
tolerability and follow-up periods of 1 month and 2 months.
In Thailand, a trial in men with occupational risk of malaria
who received monthly or bimonthly 3-day treatment courses
of dihydroartemisinin–piperaquine or placebo found 98%
protective efficacy and good tolerability but required close
supervision with weekly follow-up. This trial was done during
a period of relatively high parasite prevalence. A trial of
chloroquine chemoprophylaxis in pregnancy in Thailand
found it to be completely effective in preventing Plasmodium
vivax episodes. A comparison of tafenoquine and mefloquine
prophylaxis in Australian soldiers returning from Timor-Leste
demonstrated safety and tolerability but could not quantify
impact in preventing malaria. One trial among Thai-Burmese

Introduction
Increasing artemisinin-resistant and multidrug-resistant
malaria has been a major threat for the five countries of
the Greater Mekong subregion (Viet Nam, Cambodia,
Laos, Thailand, and Myanmar). This situation has led to
these countries committing to eliminate Plasmodium
falciparum malaria by 2023 and all malaria by 2030.1
Comprehensive national plans for malaria elimination
have been implemented in all countries in the Greater
Mekong subregion, resulting in a reduction in malaria
incidence of more than 70% from 2015 to 2019,2 and
almost 40% from 2019 to 2021.3 In Cambodia, malaria
incidence has reached very low levels, with fewer than
5000 cases reported in 2021, of which around 90% were
caused by Plasmodium vivax and 10% by P falciparum.4 In
much of the Greater Mekong subregion, includ
ing
Cambodia, the remaining malaria transmission is
82

children found proguanil to have poor prophylactic efficacy.
These trials used microscopy to detect parasites, a method
with poor sensitivity for low-density infections.
Added value of this study
This study reports the efficacy of antimalarial chemotherapy in
a low-transmission setting deliberately designed to be feasible
for scale-up for routine use as an elimination intervention.
Unlike previous chemoprophylaxis trials, it used low-intensity,
monthly follow-up and peer supervision of dosing between
follow-up visits as many of the target population spent long
periods away from the village. It is the first trial to target forest
goers, only recruiting those at highest risk of malaria to
maximise efficiency of the intervention. Choice of antimalarials
was limited to the relatively short-acting regimen of weekly
artemether–lumefantrine; previous trials have used drugs with
less frequent dosing and longer half-lives, which might affect
adherence. PCR was used to detect parasites, as it has higher
sensitivity than microscopy. Despite the low-intensity
monitoring, the chemoprophylaxis had high efficacy in
preventing malaria, and adherence to the study drug was high.
This study provides much-needed evidence for the efficacy,
tolerability, and pragmatic implementation of antimalarial
chemoprophylaxis in high-risk mobile populations in realworld settings.
Implications of all the available evidence
This study adds to existing evidence for the efficacy and
tolerability of antimalarial chemoprophylaxis in groups at high
risk of malaria in low-endemic settings. It demonstrates that
chemoprophylaxis is effective to prevent malaria in forest goers
and can be safely managed with relatively low-intensity
monthly follow-up through close engagement with, and
involvement of, the local community. Malaria
chemoprophylaxis among high-risk groups such as forest goers
could be a valuable additional tool for malaria elimination in
the Greater Mekong subregion.

concentrated in forested areas.5,6 Addressing the remain
ing parasite reservoir in forest goers is essential to reach
the goal of malaria elimination within the proposed time
frame.7 A range of interventions targeting forest goers has
been proposed, including mobile volunteerS providing
malaria diagnostics and treatment, standby treatment or
chemoprophylaxis, long-lasting insecticide-treated ham
mock nets, topical repellents, and insecticide-treated
clothing.7
Because a large proportion of the Plasmodium reservoir
in forest goers is in asymptomatic carriers with low
parasitaemias, an approach of mass screening and
treatment or reactive case detection using conventional
rapid diagnostic tests (RDTs) captures only a minority of
infections.6,8 The main Anopheles malaria vectors in the
region, Anopheles dirus, Anopheles minimus, and
Anopheles maculatus, tend to bite outside and before
www.thelancet.com/infection Vol 23 January 2023
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bedtime.9 In this epidemiological context, insecticidal
nets have limited efficacy.10 Long-lasting insecticidal
hammock nets showed only a modest protective effect in
forest villages in Cambodia.9 The quality of the housing
available in forests is limited by the available resources
consisting often of campsites covered by a suspended
tarpaulin canopy that is poorly suited to hanging bed
nets.11 Several studies have shown poor use of personal
protection measures against malaria transmission,
including in the forest.12,13 In the absence of simple,
effective, and affordable vector-control interventions,
providing forest goers with effective antimalarial
chemoprophylaxis is a promising approach to protect
them against malaria.5
We report here the results of an open-label, individually
randomised controlled trial to assess the efficacy of
malaria chemoprophylaxis among forest goers in
Cambodia. Artemether–lumefantrine was chosen as the
intervention drug because of its excellent safety profile
established over more than 20 years of extensive use. In
addition, although it remains an efficacious antimalarial,
artemether–lumefantrine has not been used as a firstline drug in Cambodia. A disadvantage of artemether–
lumefantrine is the short duration of its post-treatment
prophylactic effect, related to the elimination of
lumefantrine (terminal elimination half-life 4–6 days).14
Furthermore, artemether–lumefantrine needs to be
taken with a fat-containing drink or snack, which might
not always be available, to optimise the absorption of
the lumefantrine. Alternative antimalarials have other
disadvantages. In Cambodia, widespread resistance in
P falciparum to both artemisinins and piperaquine
precludes use of dihydroartemisinin–piperaquine.15 Arte
sunate–pyronaridine is a recently developed artemisininbased combination therapy (ACT) approved for the
treatment of falciparum malaria in the Greater Mekong
subregion and the first-line treatment in some areas.
However, its safety profile for extensive, unsupervised
use as a prophylactic treatment has not been established.16
Artesunate–mefloquine is currently the first-line treat
ment for both falciparum and vivax malaria in Cambodia
but ideally should not be used as a prophylactic to avoid
additional drug pressure on the parasite population
facilitating mefloquine resistance. Although tolerability
of weekly prophylactic dosing is reasonable, adverse
effects preclude giving treatment doses of mefloquine to
healthy individuals.17

Cambodia during 2018–19 at 142·3 cases per 1000 population
in 2018 and 86·5 in 2019, and has high forest cover.
Enrolment was between March 11 and Nov 20, 2020,
with follow-up until Feb 17, 2021. Participants aged
16–65 years who planned to travel to the forest within the
next 72 h and stay overnight, and who were willing and
able to comply with the study protocol, were included in
the study. Excluded from enrolment were women with
known pregnancy or breastfeeding or who planned to
become pregnant; individuals who had received ACT
within the previous 7 days; individuals with a history
of allergy or known contraindication to artemisinins,
lumefantrine, or multivitamins; individuals with a docu
mented or claimed history of cardiac conduction problems;
individuals with severe vomiting or diarrhoea; and
individuals with clinical malaria confirmed by an RDT.
Before enrolment, written informed consent was
obtained from participants, who received a copy of the
signed consent form. For those who could not read
or write Khmer, a fingerprint was obtained and
countersigned by an impartial witness. For participants
aged 16–18 years, written informed assent was also
obtained.
The trial was approved by the Cambodian National
Health Research Ethics Committee (reference NECHR316),
and by the University of Oxford Tropical Research Ethics
Committee (reference 23-19). The study protocol has
been published.18

Methods

Procedures

We conducted an open-label, individually randomised
controlled trial to compare the efficacy of malaria
chemoprophylaxis with artemether–lumefantrine versus
multivitamin among forest goers at 15 villages in Siem
Pang District, Stung Treng province in northeastern
Cambodia along the border with southern Laos. The
selected district had the highest malaria incidences in

Before initiation of the study, a series of community
sensitisation and engagement activities were conducted
in villages. Information focused on the concepts of
chemoprophylaxis, malaria transmission, and exposure
to mosquitos in forests. Engagement activities included
meetings conducted by a dedicated community
engagement team led by staff fluent in Khmer and local
languages, supported by the district health department,

Study design and participants

www.thelancet.com/infection Vol 23 January 2023

Randomisation and masking
Eligible participants were randomly assigned 1:1 to one of
the two treatment groups according to a computergenerated randomisation schedule. Randomisation was
in permuted blocks of size ten and stratified by village.
Individual, sealed, and sequentially numbered opaque
envelopes were provided for each trial site, with
one envelope per participant indicating the treatment
allocation. Allocation was done by trained study staff
drawing the next envelope, which contained the study
number and treatment allocation. An open-label design
was selected due to unavailability of a suitable placebo
that was identical in appearance to artemether–
lumefantrine. Masking of investigators or participants
was not possible. The randomisation procedure allowed
for drug allocation concealment before envelopes were
opened. All laboratory investigations were performed
without knowledge of the treatment allocation.
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administrative authorities, village malaria workers, and
village leaders. Details of community engagement and
acceptability have been published separately.19
At baseline, basic demographic and epidemiological data
were collected. A physical examination and a symptom
questionnaire were completed by qualified study staff.
All prescribed medications used within the previous 7 days
and a history of any drug allergies were recorded. An RDT
for the detection of malaria was performed for participants
with fever or a history of fever in the previous 24 h.
Volunteers who tested positive were excluded and received
standard antimalarial treatment from the village malaria
worker.
Together with the National Center for Parasitology,
Entomology and Malaria Control (Phnom Penh,
Cambodia), artemether–lumefantrine was chosen as the
study intervention, to be compared with a multivitamin
(with no antimalarial effect) in the control group of the
trial. Artemether–lumefantrine was obtained as Coartem
from Novartis Saglik, Istanbul, Turkey (batch: KP663;
manufacture date: August, 2019; expiry date: July, 2021).
Each tablet contained 20 mg of artemether and 120 mg
of lumefantrine. The multivitamin used in the trial was
NANPROVIT-TAB, composed of vitamin A (retinol;
2500 IU), vitamin D3 (200 IU), vitamin B1 hydrochloride
(thiamine; 5 mg), vitamin B2 (2 mg), vitamin B6
hydrochloride (pyridoxine; 2 mg), nicotinamide (4 mg),
vitamin C (30 mg), and calcium pantothenate (1 mg), and
was manufactured by Chea Chamnan Laboratoire,
Phnom Penh, Cambodia (lot number: 200847).
Participants received either two doses of artemether–
lumefantrine (four tablets per dose) or two doses of
multivitamin (one tablet per dose) per day for 3 days
initially, followed by the same daily dosing once a week
while travelling in the forest and for a further 4 weeks
after leaving the forest. The first dose of study drugs was
administered as directly observed therapy (DOT) by
trained study staff. For this first dose, the full dose or
a half dose of the study drug was repeated in case of
vomiting within 30 min or 60 min, respectively.
Participants were informed that the multivitamin had no
antimalarial effect, and all were encouraged to continue
to use other measures to protect themselves against
malaria throughout. Subsequent doses were administered
as so-called smart DOT, whereby intake was observed by
a dedicated volunteer within the group of forest goers.
Participants were followed up between days 28 and 35
(1 month), between days 56 and 63 (2 months), and
between days 84 and 91 (3 months)—ie, after each of
three consecutive periods of 28 days plus a 7-day window.
During follow-up, data were collected on duration of stay
and locations visited in the forest, purpose of forest
visits, accompanying forest goers, and potential risk
factors for malaria infection. Brief physical examinations
were performed, including aural temperature, and
a symptom questionnaire was completed during each
follow-up visit by qualified staff members. Participants
84

were asked to report any diagnostic tests or treatment for
malaria since the last follow-up visit. In case participants
declared at the time of the follow-up visit no intention to
return to the forest in the coming 4-week period, no
further follow-up visits were scheduled, but 4 weeks of
terminal chemoprophylaxis following their last day in
the forest were completed. For those who declared an
intention to return to the forest, they continued in the
study for another period of 28 days up to a maximum of
three periods.
Passive surveillance of clinical malaria continued
throughout the study period, and records from local
treatment providers were collected routinely. For
participants who had an episode of RDT-confirmed
clinical malaria at any time after enrolment up to the last
follow-up visit, dried blood spots (three spots, 200 µL for
each spot) for parasite DNA were collected on Whatman
filter paper (Cytivia, Marlborough, MA, USA) by the
village malaria worker. Laboratory procedures were the
same as for baseline blood spot samples described below.
Participants with malaria were treated by the village
malaria worker in accordance with Cambodian malaria
treatment guidelines (artesunate–mefloquine for both
vivax and falciparum malaria).
Dried blood spots (three 200 µL spots) were collected on
Whatman filter paper from finger pricks for parasite PCR
from all participants at baseline, immediately before drug
administration, and at each follow-up visit. Samples were
stored in a plastic ziplock bag with silica gel and were sent
to the Molecular Tropical Medicine Laboratory at Mahidol
Oxford Tropical Medicine Research Unit, Bangkok,
Thailand. Parasite DNA was extracted using the QIAmp
DNA Mini Kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. For Plasmodium identi
fication, nested PCR targeting the 18S rRNA gene was
performed as previously described; this method has
a lower limit of detection of 1–10 parasites per μL.20 In
brief, 1 μL of genomic DNA was used in a 20 μL reaction
with outer primers rPLU1 and rPLU5. Then, nested PCR
was performed with 2 μL of the primary PCR product and
species-specific primers for the four human malaria
species in separate reaction tubes. All PCR products were
separated on 2% agarose gels. After staining with
ethidium bromide, the gel was visualised under an
ultraviolet light.
For assessment of study drug adherence in 43 randomly
selected study participants who received artemether–
lumefantrine, a 1 mL venous blood sample was collected
in pre-chilled heparin tubes at the 4th, 8th, and 12th week
follow-up visits for assessment of plasma lumefantrine
concentrations. Allowing for anticipated loss to follow-up,
this method would provide 100 samples for analysis. This
testing was feasible only in villages in which pre-chilled
heparin tubes could be used during follow-up.
Randomisation was done by computer using the list of
enrolled individuals in these villages. Samples were
transported back on ice to the local laboratory for
www.thelancet.com/infection Vol 23 January 2023
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centrifugation at 2000 g for 7 min, after which 0·5 mL
plasma was obtained and stored in liquid nitrogen.
Plasma samples were sent on dry ice to the Pharmacology
Laboratory at Mahidol Oxford Tropical Medicine
Research Unit, Bangkok, Thailand, for measurement of
lumefantrine concentrations using published methods.21

1613 individuals assessed for eligibility

133 excluded
1 not aged between 16 and 65 years
15 no plan to travel to the forest within the next
3 days and stay overnight
11 no willingness to comply with the protocol
73 no ability to comply with the protocol for the
duration of the study
15 pregnant or breastfeeding
2 signs or symptoms of clinical malaria (febrile or
history of fever in the previous 24 h), confirmed
by rapid diagnostic test
11 allergy or known contraindication to artemisinins,
lumefantrine, or multivitamins
1 severe vomiting or diarrhoea
4 documented or claimed history of cardiac
conduction problems

Outcomes
The primary outcome was a composite endpoint of either
clinical malaria with any Plasmodium species within 1–28,
29–56, or 57–84 days, or subclinical infection detected by
PCR on days 28, 56, or 84. The first secondary outcome
was the same as the primary outcome but for each
species. Incidence of adverse events by study group as a
measure of tolerability and safety and blood plasma
concentrations of lumefantrine from 43 randomly
selected individuals at each follow-up visit were additional
prespecified secondary endpoints. Other secondary
outcomes will be reported elsewhere separately and are
listed in appendix 1 (p 12).

Statistical analysis
It was anticipated that there would be a 5% P falciparum
PCR positivity rate in the control group during each
28-day follow-up period. A total of 1605 person-months
at risk (a month being 28 days) per group would be
sufficient to detect a reduction in the PCR positivity
rate of at least 40% with 80% power and 5% significance
level—ie, 5% in those receiving multivitamin versus
3% in those receiving artemether–lumefantrine.
To account for reduction in statistical power due to
repeated observations in the same participant and loss
to follow-up, we planned to include approximately
600 additional person-months at risk in each study
group. Based on these considerations, the overall
sample size was estimated to be 4400 person-months at
risk (ie, 2200 person-months at risk in the treatment
group and 2200 person-months at risk in the control
group). Thus, with expected event rates of 5% in the
control group versus 3% in the intervention group, we
expected to observe 110 events in the control group and
66 events in the intervention group, giving a total of
176 events. The sample size calculations were
performed in Stata IC version 15. The trial was stopped
before the planned sample size was reached because
enrolment and follow-up were slowed substantially by
restrictions imposed due to the COVID-19 pandemic,
and the grants that funded the trial came to an end.
The primary outcome was analysed by intention-totreat, followed by a per-protocol analysis. Efficacy
of artemether–lumefantrine versus multivitamin, here
defined as the proportion of participants who remained
uninfected over the 28-day episode, was summarised
using proportions and 95% CIs. Crude proportions were
calculated using the exact binomial 95% CIs. The absolute
risk differences, protective efficacies, and risk ratios
between artemether–lumefantrine and multivitamin
www.thelancet.com/infection Vol 23 January 2023

1480 enrolled and randomly assigned

738 assigned and received
artemether–lumefantrine

742 assigned and received multivitamin

738 in intention-to-treat analysis*

742 in intention-to-treat analysis*

78 lost to follow-up
25 withdrew consent
4 other (pregnancy)

79 lost to follow-up
48 withdrew consent
4 other (pregnancy)

607 in per-protocol analysis

635 in per-protocol analysis

Figure 1: Trial profile
*Within the intention-to-treat population, there were 713 complete cases in the artemether–lumefantrine group
and 714 complete cases in the multivitamin group.

were reported along with the corresponding 95% CIs.
The robust standard errors were used to adjust for
intracluster correlation of months at risk from the same
individual (clustering within individual) using the
generalised estimating equation approach with exchange
able correlation structure. Tests of significance were at
the 5% level.
Best and worst case scenarios were initially planned to
handle missing data.18 However, there is increasing
literature that indicates that complete-case analysis
performs similarly to multiple imputation in ran
domised controlled trials and sometimes even better
than multiple imputation.22–24 Our assumption is that
the outcome data in our study are likely to be missing
completely at random and in this case, complete-case
analysis would probably perform better than extreme
case (best and worst case) analysis. There is an
amendment section in the statistical analysis plan
(appendix 2 p 16) with more details.
Adverse events were graded according to Common
Terminology Criteria for Adverse Events version 5.0;

See Online for appendix 1

See Online for appendix 2
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Artemether–
lumefantrine (n=738)

Multivitamin (n=742)

Total (n=1480)

Demographics
Age, years

29 (21–40)

30 (21–40)

30 (21–40)

Sex
Male

546 (74%)

589 (79%)

1135 (77%)

Female

192 (26%)

153 (21%)

345 (23%)

Weight, kg

52 (7)

52 (8)

52 (7)

Nationality
Khmer
Laos

737 (>99%)

740 (>99%)

1477 (>99%)

1 (<1%)

2 (<1%)

3 (<1%)

Occupation
Farmer

706 (96%)

712 (96%)

1418 (96%)

Student

10 (1%)

15 (2%)

25 (2%)

Soldier

11 (1%)

8 (1%)

19 (1%)

Teacher

5 (<1%)

3 (<1%)

Housewife

3 (<1%)

0

8 (<1%)
3 (<1%)

Fishing

1 (<1%)

1 (<1%)

2 (<1%)
2 (<1%)

Village leader

1 (<1%)

1 (<1%)

Village malaria worker

0

1 (<1%)

1 (<1%)

Seller

0

1 (<1%)

1 (<1%)

Environment department

1 (<1%)

0

1 (<1%)

Medical history*
Previous malaria episodes

427 (58%)

Dengue fever

0

421 (57%)

848 (57%)

1 (<1%)

1 (<1%)

Symptoms
Headache

30 (4%)

26 (4%)

56 (4%)

Dizziness

18 (2%)

20 (3%)

38 (3%)

9 (1%)

14 (2%)

23 (2%)

12 (2%)

6 (1%)

18 (1%)

Abdominal pain
Joint pain
Fatigue

4 (<1%)

4 (<1%)

Muscle pain

5 (<1%)

2 (<1%)

8 (<1%)
7 (<1%)

Diarrhoea

4 (<1%)

1 (<1%)

5 (<1%)
3 (<1%)

Itching or rash

1 (<1%)

2 (<1%)

Nausea

0

1 (<1%)

1 (<1%)

Vomiting

0

1 (<1%)

1 (<1%)

36·5 (0·4)

36·6 (0·4)

Physical examination
Tympanic temperature†, °C

36·6 (0·4)

Movement abnormality

0

0

0

Skin abnormality

0

0

0

Eye abnormality

0

0

0

Breathing abnormality

0

0

0

Speech abnormality

0

0

0

Hearing abnormality

0

0

0

Data are median (IQR), n (%), or mean (SD). *History within previous 5 years. †At screening.

Table 1: Baseline characteristics

November, 2017.25 All adverse event summaries referred
to adverse events that newly started or increased in
intensity after study drug administration. Adverse event
summaries were generated for all adverse events that
occurred after study drug administration, until the end of
follow-up. Adverse events were reported for all
participants by study group according to their incidence,
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intensity, and relationship to the study drug. Serious
adverse events were reported separately. Statistical
analysis was done using Stata MP version 16.
Monitoring was coordinated by the Clinical Trials
Support Group within the Mahidol Oxford Tropical
Medicine Research Unit. The trial is registered with
ClinicalTrials.gov (NCT04041973) and is complete.

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report.

Results
Between March 11 and Nov 20, 2020, a total of 1613 people
were screened and 1480 enrolled (figure 1). The main
reasons for exclusion (n=133) were not being able (n=73)
or willing (n=11) to comply with the study protocol, no
plan to travel to the forest within the next 3 days and stay
overnight (n=15), and pregnancy or breastfeeding (n=15).
Thus, 1480 participants received study drugs, 738 in the
artemether–lumefantrine group and 742 in the
multivitamin group. The two intervention groups were
well balanced for all baseline characteristics (table 1). The
median age was 30 years (IQR 21–40), 77% of participants
were male, 96% were farmers, and 57% had previous
malaria episodes. Symptoms at baseline were uncommon
(120 [8%] of 1480 participants). Median time spent in the
forest per participant episode was 17 nights (IQR 6–26) in
each of the artemether–lumefantrine and multivitamin
groups.
The proportion of participants who had parasitaemia
detected by PCR at baseline was similar in both
treatment groups (83 [11%] of 738 in the artemether–
lumefantrine group and 86 [12%] of 742 in the
multivitamin group). 713 participants in the artemether–
lumefantrine group and 714 in the multivitamin group
had a PCR result or confirmed clinical malaria by RDT
during follow-up. Over the whole follow-up period, there
were 14 episodes due to P falciparum infection
(parasitaemia or clinical malaria), 166 due to P vivax, two
due to Plasmodium malariae, and three due to mixed
infections with both P falciparum and P vivax (figure 2
and appendix 1 pp 13–14). Combining all Plasmodium
species, 19 (3%, 95% CI 2–4) of 713 participants had
parasitaemia or clinical malaria in the artemether–
lumefantrine group and 123 (17%, 15–20) of 714 in the
multivitamin group; absolute risk difference 15%
(95% CI 12–18; p<0·0001). This result translates to
a protective efficacy of 85% (95% CI 75–90; p<0·0001)
and a risk ratio of 0·15 (95% CI 0·1–0·25) in favour of
artemether–lumefantrine (see appendix 1 p 5 for the
intention-to-treat analysis and appendix 1 p 6 for the perprotocol analysis). The proportion of participants with
parasitaemia or clinical malaria at 1, 2, or 3 months of
follow-up was also lower in the artemether–lumefantrine
group, with protective efficacies of 92% (95% CI 81–97)
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at 1 month, 81% (64–90) at 2 months, and 78% (52–89) at
3 months (appendix 1 p 5). Stratification of the results
according to the Plasmodium PCR positivity status at
day 0 showed that the efficacy of chemoprophylaxis with
artemether–lumefantrine was higher in both groups
overall and at all individual timepoints (appendix 1
pp 4–11).
The proportion of participants who had symptomatic
or asymptomatic P falciparum infections during the
follow-up period was lower with artemether–
lumefantrine than with multivitamin: 0·3% (95% CI
0·03–1·01; two of 713) versus 1·7% (0·9–2·9; 12 of 714;
absolute risk difference 1·4%, 95% CI 0·4–2·4, p=0·013;
protective efficacy 83%, 95% CI 26–96, p=0·019;
figure 2B; appendix 1 p 7). Fewer than ten participants
in each group had a PCR-positive result for P falciparum
on enrolment, hence an analysis for this subgroup was
not meaningful; however, we have provided a summary
for completeness in appendix 1 (p 6).
The proportion of participants who had symptomatic
or asymptomatic P vivax infections was lower in the
artemether–lumefantrine than the multivitamin group
(figure 2C; appendix 1 pp 8–11) for all follow-up months
combined: 18 (3%, 95% CI 2–4) of 713 participants in the
artemether–lumefantrine group versus 112 (16%, 13–19)
of 714 in the multivitamin group (absolute risk
difference 13%, 95% CI 10–16, p<0·0001; protective
efficacy 84%, 95% CI 74–90, p<0·0001). When stratified
by the presence of P vivax parasitaemia at baseline, the
artemether–lumefantrine chemoprophylactic effect for
developing P vivax infection was numerically larger
for participants without parasitaemia at baseline:
protective efficacy for all months was 86% (74–92,
p<0·0001) in PCR-negative participants and 80% (57–90;
p<0·0001) in PCR-positive participants (appendix 1 p 8).
In addition to the higher incidence, there was also longer
persistence of P vivax infections (post-hoc analysis) in
the multivitamin group compared with the artemether–
lumefantrine group (appendix 1 pp 2, 12). Participants in
the multivitamin group could have been infected and
therefore potentially transmitting P vivax for
69 person-months (69 of 1819 person-months at risk in
total) compared with 10 person-months (10 of 1796) in
the artemether–lumefantrine group (incidence rate ratio
6·8, 95% CI 3·5–14·8, p<0·0001; appendix 1 p 12).
Overall loss to follow-up during months 1, 2, and 3,
respectively, was 5% (39 of 738), 7% (44 of 629), and 8%
(48 of 569) in the artemether–lumefantrine group and
5% (35 of 742), 8% (53 of 649), and 7% (41 of 581) in the
multivitamin group (appendix 1 pp 15–16). Overall
reported adherence to the full course of medication
during each follow-up period was 97% (95% CI 96–98;
1797 completed courses out of 1854 courses started) in
the artemether–lumefantrine group and 98% (97–98;
1842 completed courses out of 1885 courses started) in
the multivitamin group (appendix 1 p 17). There were no
significant differences in any of the measures of

Figure 2: Percentage of participants with malaria infection over time
Malaria infection was defined as PCR parasite positivity on days 0 (baseline), 28–35 (month 1), 56–63 (month 2),
or 84–91 (month 3), or a case of confirmed clinical malaria during month 1, month 2, or month 3.

adherence between the artemether–lumefantrine group
and the multivitamin group (appendix 1 p 17).
There were no significant differences between the
artemether–lumefantrine group and multivitamin group
in vomiting within 1 h (table 2). Although rare, there
were higher rates of abdominal pain, fatigue, muscle
pain, diarrhoea, and loss of appetite in the artemether–
lumefantrine group than the multivitamin group, with
overall prevalences of adverse events of 1·9% (355 events
in 18 806 doses) in the artemether–lumefantrine group
and 1·1% (207 events in 19 132 doses) in the multivitamin
group (p<0·0001; table 2). No serious adverse events
were reported as related to study drugs. There were
two serious adverse events in the artemether–lume
fantrine group and three in the multivitamin group.
These events comprised one episode of dengue fever and
one episode of hypoglycaemia in the artemether–
lumefantrine group, and one suspected hepatocellular
carcinoma and two accidents in the multivitamin group
(table 2, appendix 1 pp 18–19).
Median time from the last dose of artemether–
lumefantrine to blood sampling for lumefantrine
assessment was 1 day (IQR 1–2) for those with detectable
plasma lumefantrine and 1 day (1·00–1·75) for those
with undetectable plasma lumefantrine. Of 105 blood
samples taken from 43 randomly selected participants
from three villages in the artemether–lumefantrine
group at follow-up (40 first, 37 second, and 28 third
follow-up visits), 99 (94%) were positive for lumefantrine
and 83 (79%) for desbutyl-lumefantrine. Five of the
six participants who had no detectable plasma lumefantrine
or desbutyl-lumefantrine said they had taken the
artemether–lumefantrine in the correct dose with food as
per the schedule, and intake had been observed by the
forest team leader (smart DOT). The remaining participant
said they had missed the last dose. Of the 105 participants
with a drug measurement, none had a confirmed clinical
episode of malaria during follow-up, and none of the
six participants with undetectable lumefantrine and
five (5%) of the 99 participants with detectable drug
concentrations were positive by PCR for P vivax.
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Artemether–
lumefantrine
Number of participants

Multivitamin

p value*

738

742

··

Course 1 (all participants)

738

742

··

Course 2 (total attended follow-up visit
1 plus total rejoined second follow-up
period)

715

721

··

Course 3 (total attended follow-up visit
2 plus total rejoined third follow-up
period)

611

621

··

716

721

··

18 806

19 132

Number of participants participating in courses

Number of participants who took more
than one dose†
Number of doses taken
Vomiting within 1 h‡

1 (<0·1%)

0

··
0·50

Adverse events‡
Headache

71 (0·4%)

51 (0·3%)

0·070

Abdominal pain

52 (0·3%)

24 (0·1%)

0·0012

Dizziness

45 (0·2%)

32 (0·2%)

0·14

Fatigue

34 (0·2%)

17 (<0·1%)

0·017

Joint pain

28 (0·1%)

16 (<0·1%)

0·071

Muscle pain

23 (0·1%)

11 (<0·1%)

0·040

Diarrhoea

19 (0·1%)

8 (<0·1%)

0·035

Fever

15 (<0·1%)

7 (<0·1%)

0·092

Loss of appetite

15 (<0·1%)

4 (<0·1%)

0·012

Cough

14 (<0·1%)

11 (<0·1%)

0·56

Sore throat

11 (<0·1%)

8 (<0·1%)

0·50

Nausea

7 (<0·1%)

4 (<0·1%)

0·39

Itching

3 (<0·1%)

2 (<0·1%)

0·69

3 (<0·1%)

1 (<0·1%)

0·37

15 (<0·1%)

11 (<0·1%)

Vomiting
Others
All adverse events

355 (1·9%)

Serious adverse events‡§

2 (<0·1%)

207 (1·1%)
3 (<0·1%)

0·44
<0·0001
1·00

Data are n, n/N (%), or n (%). *Comparing between groups using Fisher’s exact test. †All participants (738 in the
artemether–lumefantrine group, 742 in the multivitamin group) took the first dose after enrolment; for 22 and
21 participants, respectively, it was not recorded that they took any further doses. ‡The denominator for the
percentages is the total number of doses taken in each group (18 806 in the artemether–lumefantrine group, 19 312 in
the multivitamin group). §Serious adverse events included one case of dengue fever and one case of hypoglycaemia in
the artemether–lumefantrine group, and one suspected hepatocellular carcinoma and two accidents in the
multivitamin group.

Table 2: Treatment course uptake and adverse events

Discussion
The trial found that it is feasible and effective to give forest
goers antimalarial chemoprophylaxis with artemether–
lumefantrine. Antimalarial chemoprophylaxis with
artemether–lumefantrine had a large impact on the
proportions of participants with subsequent parasitaemia:
3% among those who received chemoprophylaxis
compared with 17% in the control group. A marked impact
on parasitaemia occurred irrespective of whether
participants were PCR-positive on enrolment. The large
differences in outcome between the treatment groups
strongly suggest that the forest goers adhered to their
respective regimens, in concordance with the other
measures of adherence reported. Adverse events reported
by trial participants receiving artemether–lumefantrine
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and multivitamin were similar, reinforcing the well
known safety and tolerability of artemether–lumefantrine.
Most infections were with P vivax, and a large
proportion of these were probably caused by relapses
from pre-existing liver hypnozoites, rather than new
infections. Relapses of vivax malaria are not prevented by
a blood schizontocidal drug such as artemether–
lumefantrine but can be suppressed by artemether–
lumefantrine, and the findings do suggest a major
impact on persistent P vivax carriage. Participants in the
control group were found to carry P vivax infections for
69 person-months compared with 10 person-months in
the artemether–lumefantrine group. This more than
six-fold difference might have provided a degree of
indirect protection for forest goers in the control group
who accompanied those receiving artemether–lume
fantrine chemoprophylaxis and could have contributed
to the decrease in parasite prevalence over time observed
in the control group. A potential indirect protective effect
of artemether–lumefantrine on the control group
might therefore have resulted in slightly underestimating
the prophylactic protective effect of artemether–lume
fantrine. The study detected only 11 clinical malaria
episodes during the study period (0·4% of participants in
the artemether–lumefantrine group and 1% in the
control group), suggesting a similar impact on clinical
malaria as on parasitaemia.
The findings come at a time when forested regions
have become some of the last remaining foci of malaria
transmission in southeast Asia. A range of interventions
to interrupt malaria transmission has been tried with
mixed success in the Greater Mekong subregion.5 Some
interventions such as mosquito-proof hammocks are
cumbersome and have been shown to have low efficacy,9
while others, including mass screening and treatment,
have yet to show benefit.26 The use of antimalarial
chemoprophylaxis for high-risk groups is not a new
concept.27 Seasonal malaria chemoprevention targets
children growing up in the Sahel countries, where the
transmission intensity is in general much higher than
in the Greater Mekong subregion.28,29 Yet the parasite
prevalence in forest goers in this study of over 10% at
baseline is relatively high. Seasonal malaria chemo
prevention is popular with the target population and
has been found to be highly cost-effective.19 More than
10 million children living in the Sahel now receive
seasonal malaria chemoprevention annually. Due to the
fundamental differences in malaria epidemiology
between the Sahel and Greater Mekong subregion,
adult forest goers and not children are at highest risk in
the Greater Mekong subregion. Other than in the
military, this study is the first time that widescale
antimalarial chemoprophylaxis has been targeted at
high-risk groups in the Greater Mekong subregion. It is
generally recommended that different antimalarials are
used for first-line malaria treatment and for mass
treatment to reduce the risk of developing drug
www.thelancet.com/infection Vol 23 January 2023
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resistance. In Cambodia, the first-line antimalarial
treatment is artesunate–mefloquine. When deploying
artemether–lumefantrine in the context of chemo
prophylaxis, adherence is very important because with
adherence to a full 3-day course the risk of the parasite
developing resistance is not greater than with usual
malaria treatment since the window for selection is
the same.30
The study was conducted in 2020 during the first year
of the COVID-19 pandemic, which made access to study
sites difficult. Repeated lockdowns prohibited large
gatherings, including sensitisation meetings with forest
goers, and required unusual flexibility from all members
of the study team throughout the study period. The well
balanced baseline characteristics of both study groups
indicate that the randomisation was achieved successfully
despite the constraints. Restrictions due to COVID-19
slowed enrolment and follow-up, and thus the trial had
to be stopped before reaching the planned sample size
once the grants came to an end. Despite this, we believe
the statistically significant and approximately six-fold
difference between study groups in subsequent
infections is sufficiently reliable evidence from which to
report a real effect of the intervention. The COVID-19
pandemic had no noticeable negative impact on malaria
control in Cambodia, despite valid concerns that diag
nosis and treatment would be undermined. Quite the
opposite has occurred, and clinical malaria has reached
unprecedented low levels in Cambodia, while numbers
of malaria diagnostic tests performed suggests this
observation is not due to under-reporting. Our study
detected only 11 clinical malaria cases, which was
insufficient to detect statistically significant differences
between study groups.
Given the nature of forest work, DOT could not be
provided by a trained health worker, and instead smart
DOT was used, whereby the first dose was observed by
a health worker and subsequent doses supervised
by a volunteer forest worker in each group. This meant
the study was conducted closer to a real-world setting.
Despite this, high participant adherence was achieved,
which is supported by the finding that the large majority
of malaria cases occurred in the control group.
The antimalarial regimen used in this study for
chemoprophylaxis did not include 8-aminoquinolines
required for the prevention of P vivax relapse, without
which the interruption of transmission of P vivax
becomes an extended process. Given the increasing
relative importance of vivax malaria in the Greater
Mekong subregion, future studies should consider the
addition of 8-aminoquinolines, such as primaquine or
tafenoquine.31 Tafenoquine would provide both radical
cure of P vivax and causal prophylaxis of P falciparum
infections, but will require highly reliable screening for
glucose-6-phosphate dehydrogenase (G6PD) deficiency
of forest goers, because of the risk of haemolysis. With
a new generation of point-of-care diagnostic tools for
www.thelancet.com/infection Vol 23 January 2023

G6PD deficiency approaching regulatory approval, such
a strategy might become feasible in the future.32
A combination of ACT and tafenoquine chemoprophylaxis
should be considered for elimination of both species,
particularly where P vivax predominates.
Limitations of artemether–lumefantrine are the rel
atively short duration of the prophylactic effect compared
with other ACTs, the dependence on concomitant intake of
a fat, and the twice daily dosing. Advantages of artemether–
lumefantrine for chemoprophylaxis in Cambodia are the
antimalarial efficacy, that it is not used as first-line
antimalarial treatment, and the very good safety and
tolerability profile. Good tolerability and an excellent safety
profile were especially important as the participants
receiving it would be otherwise healthy and thus potentially
less likely to accept drug-related symptoms than patients
with clinical malaria. In other studies,33,34 artemether–
lumefantrine has been associated with mild adverse drug
reactions—chiefly, headache, dizziness, weakness, muscle
or joint pain, and tiredness. We also observed a small, selfreported increase of these symptoms in the present study
in those taking artemether–lumefantrine. The study shows
that, as anticipated, artemether–lumefantrine has a benign
tolerability profile and in this regard is suitable for
chemoprophylaxis. If other drugs are selected for
chemoprophylaxis, it will be important that they are also
reasonably well tolerated, or adherence might fall below
the high levels observed in the present study. Because of
the urgency of using this strategy, both Cambodia and
Laos have recently implemented chemoprophylaxis in
forest goers (artesunate–mefloquine in Cambodia and
artesunate–pyronaridine in Laos).
In conclusion, this study demonstrated that
chemoprophylaxis with artemether–lumefantrine was
acceptable, well tolerated, and reduced by approximately
six-fold the number of subsequent malaria infections
over a 3-month period. Malaria chemoprophylaxis among
high-risk groups such as forest goers is a valuable
additional tool for malaria elimination in the Greater
Mekong subregion.
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